Are GlaxoSmithKline shares under-valued?

GlaxoSmithKline shares are likely under-priced given the company’s current market position, near-term strategy and future pipeline prospects.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) has been a little late to the diversification party, but with the planned spin-out of its consumer health division this year, and a couple of impactful launches in the market, the prospects for this currently underperforming stock are good – and probably better than its share price right now suggests.

Ostensibly, GlaxoSmithKline’s broad geographic footprint – and an operating model that includes pharmaceuticals, consumer health, and vaccines – would appear to give this Big Pharma player the sturdiness to weather a multitude of storms. But at a time when the prevailing trend has been a move towards pure-play pharmaceuticals and the higher margins this commands, GlaxoSmithKline appears to be somewhat behind the times… an impression the company is seeking to rectify with the planned spin-out of the consumer health joint venture it co-owns with Pfizer in 2021.

GlaxoSmithKline’s dividend has been held flat for several years, its shares yielding a return of 5-6%, which has been very reasonable for a company of its size. However, GlaxoSmithKline recently indicated a dividend reduction to finance pipeline development – essentially to buy in early stage assets. While GlaxoSmithKline has talked up its current pipeline – the 20 or so products in development, half of which with blockbuster potential – many will not come to fruition until 2026. Inorganic growth is therefore an important means of bulking up on pipeline opportunities for the next few years to provide something of a revenue bridge to the outer years when GlaxoSmithKline’s home-grown assets hit the market.

In the meantime, GlaxoSmithKline is capitalising on its key strengths, namely leadership in respiratory and HIV, and making waves with recent landmark approvals. In September 2020, GlaxoSmithKline received FDA approval for Trelegy Ellipta, the first once-daily, three-in-one drug to treat both asthma and COPD, beating AstraZeneca to the post. And Nucala – GlaxoSmithKline’s injectable biologic treatment for asthma – was the first to be approved for use in a rare eosinophil driven disease. In January 2021, GlaxoSmithKline secured US approval for the first injectable long-acting treatment for HIV. Previous to this, GlaxoSmithKline had another first, with the April 2019 FDA approval of Dovato, the first complete two-drug regimen to be approved in the US for the treatment of HIV.

On balance, GlaxoSmithKline’s near-term prospects look great, with a convincing in-market presence, and imminent splintering0off of the consumer health division sure to improve the operating margin of the pure-play Pharma that’s left. Further, GlaxoSmithKline’s vaccine and infectious disease experience will undoubtedly stand the company in good stead at a time when keeping up with the latest Covid-19 mutations has spawned a sub-industry in the vaccine sector. It’s the long term where the greatest uncertainty lies for GlaxoSmithKline shares, and despite positivity around the company’s pipeline, it is perhaps too heavily loaded to the outer years for my comfort.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Pam Narang has no position in any company mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Is the S&P 500 going to 10,000 by 2030? This expert thinks so

One stock market strategist sees animal spirits taking hold and driving the S&P 500 index even higher by the end…

Read more »

Investing Articles

I’m expecting my Phoenix Group shares to give me a total return of 25% in 2025!

Phoenix Group shares have had a difficult few months but that doesn't worry Harvey Jones. He loves their 10%+ yield…

Read more »